^
Association details:
Biomarker:No biomarker
Cancer:Thymic Carcinoma
Regimen:VIP (cisplatin + etoposide IV + ifosfamide)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Thymic Carcinoma: FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS...Other Recommended…Etoposide/ifosfamide/cisplatin...Etoposide 75 mg/m2 on days 1–4; Ifosfamide 1.2 g/m2 on days 1–4; Cisplatin 20 mg/m2 on days 1–4...Administered every 3 weeks...